The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Emerging Infections in Burns
Open accessAbstract
BACKGROUND: Patients who suffer severe burns are at higher risk for local and systemic infections. In recent years, emerging resistant pathogens have forced burn care providers world wide to search for alternative forms of treatment. Multidrug-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter spp., and various fungal strains have been the major contributors to the increase in morbidity and mortality rates. Multi-drug-resistant S. aureus remains the major cause of gram-positive burn wound infections world wide. Treatment strategies include rigorous isolation protocols and new types of antibiotics where necessary. METHODS: We reviewed 398 severely burned patients (burns >40% total body surface area [TBSA]) admitted to our hospital between 2000 and 2006. Patients who did not contract multi-drug-resistant gram-negative organisms during their hospital course and received our standard antibiotic regimen-vancomycin and piperacillin/tazobactam-served as controls (piperacillin/tazobactam; n = 280). The treatment group consisted of patients who, during their acute hospital stay, developed infections with multi-drug-resistant gram-negative pathogens and were treated with vancomycin and colistin for at least three days (colistin; n = 118). RESULTS: Gram-negative organisms continue to cause the most severe infections in burn patients. Colistin has re-emerged as a highly effective antibiotic against multiresistant Pseudomonas and Acinetobacter infections of burns. Patients who required colistin therapy had a significantly larger average total and full-thickness burn than patients treated with piperacillin/tazobactam and vancomycin, and the mortality rate was significantly higher in the colistin group (p < 0.05). However, there was no significant difference between the colistin and piperacillin/tazobactam groups in the incidence of neurotoxicity, hepatic toxicity, or nephrotoxicity. The main fungal pathogens in burn patients are Candida spp., Aspergillus spp., and Fusarium spp. A definitive diagnosis is more difficult to obtain than in bacterial infections. Amphotericin B and voriconazole remain the two most important anti-fungal substances in our practice. CONCLUSIONS: Innovations in fluid management, ventilatory support, surgical care, and antimicrobial therapy have contributed to a significant reduction in morbidity and mortality rates in burn patients. Vancomycin and clindamycin are the two most important reserve antibiotics for methicillin-resistant Staphylococcus aureus infection. Oxazolidinones and streptogramins have showed high effectiveness against gram-positive infections. Colistin has re-emerged as a highly effective antibiotic against multiresistant Pseudomonas and Acinetobacter infections. Current challenges include Candida, Aspergillus, and molds. The development of new agents, prudent and appropriate use of antibiotics, and better infection control protocols are paramount in the ongoing battle against multi-resistant organisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The epidemiology of sepsis in the United States from 1979 through 2000
Martin, G. S., Mannino, D. M., Eaton, S., & Moss, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022139 · Cited by 5,841
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Manual of clinical microbiology
Drasar, B. (2003) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(03)90074-5 · Cited by 2,594
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989.
Banerjee, S. N., Emori, T. G., Culver, D. H., Gaynes, R. P., Jarvis, W. R., Horan, T., Edwards, J. R., Tolson, J., Henderson, T., Martone, W. J., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90349-3 · Cited by 880
Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831
Polymyxin and Related Peptide Antibiotics
Storm, D. R., Rosenthal, K. S., & Swanson, P. E. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.003451 · Cited by 759
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance
Krcmery, V., & Barnes, A. J. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1151 · Cited by 733
American Burn Association Consensus Conference to Define Sepsis and Infection in Burns
Greenhalgh, D. G., Saffle, J. R., Holmes, J. H., Gamelli, R. L., Palmieri, T. L., Horton, J. W., Tompkins, R. G., Traber, D. L., Mozingo, D. W., Deitch, E. A., et al. (2007) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e3181599bc9 · Cited by 695
Self-citation
Cited by
Burn wound healing and treatment: review and advancements
Rowan, M. P., Cancio, L. C., Elster, E. A., Burmeister, D. M., Rose, L. F., Natesan, S., Chan, R. K., Christy, R. J., & Chung, K. K. (2015) · Critical Care · doi:10.1186/s13054-015-0961-2 · Cited by 1,015
Burn injury: Challenges and advances in burn wound healing, infection, pain and scarring
Wang, Y., Beekman, J., Hew, J., Jackson, S., Issler-Fisher, A. C., Parungao, R., Lajevardi, S. S., Li, Z., & Maitz, P. K. M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.018 · Cited by 696
The Dynamics of the Skin’s Immune System
Nguyen, A. V., & Soulika, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081811 · Cited by 694
Animal models in burn research
Abdullahi, A., Amini-Nik, S., & Jeschke, M. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1612-5 · Cited by 463
Self-citationDel Pozo, J. L. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1417036 · Cited by 453
Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update
Saiman, L., Siegel, J. D., LiPuma, J. J., Brown, R. F., Bryson, E. A., Chambers, M. J., Downer, V. S., Fliege, J., Hazle, L. A., Jain, M., et al. (2014) · Infection Control & Hospital Epidemiology · doi:10.1086/676882 · Cited by 387
Norbury, W., Herndon, D. N., Tanksley, J., Jeschke, M. G., Finnerty, C. C., & on Behalf of the Scientific Study Committee of the Surgical Infection Society (2016) · Surgical Infections · doi:10.1089/sur.2013.134 · Cited by 337
Self-citationThe enhanced permeability retention effect: a new paradigm for drug targeting in infection
Azzopardi, E. A., Ferguson, E. L., & Thomas, D. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks379 · Cited by 312
Candida Species Biofilms’ Antifungal Resistance
Silva, S., Rodrigues, C., Araújo, D., Rodrigues, M., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010008 · Cited by 302
Burns: Classification, Pathophysiology, and Treatment: A Review
Żwierełło, W., Piorun, K., Skórka-Majewicz, M., Maruszewska, A., Antoniewski, J., & Gutowska, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043749 · Cited by 264
Healthcare-associated viral and bacterial infections in dentistry
Laheij, A. M. G. A., Kistler, J. O., Belibasakis, G. N., Välimaa, H., de Soet, J. J., & 2011, E. O. M. W. (. (2012) · Journal of Oral Microbiology · doi:10.3402/jom.v4i0.17659 · Cited by 116
Nanozybiotics: advancing antimicrobial strategies through biomimetic mechanisms
Zhou, C., Wang, Q., Cao, H., Jiang, J., & Gao, L. (2024) · Advanced Materials · doi:10.1002/adma.202403362 · Cited by 114
Metadata
- Authors
- Branski, L. K., Al-Mousawi, A., Rivero, H., Jeschke, M. G., Sanford, A. P., & Herndon, D. N.
- Venue
- Surgical Infections
- Publisher
- SAGE Publications
- Published
- 2009-10
- Volume
- 10
- Issue
- 5
- Pages
- 389-397
- ISSN
- 1096-2964 (ISSN-L)
- 1557-8674
- OpenAlex
- W2039729207
- Cited by
- 365
- References
- 44
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.